How I treat relapsed and/or refractory multiple myeloma
The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2020-09-01
|
| Col·lecció: | Hematology Reports |
| Matèries: | |
| Accés en línia: | https://www.pagepress.org/journals/index.php/hr/article/view/8955 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|